We are developing small-molecule medicines, with clinically validated mechanisms of action, to address oncology and metabolic diseases with large unmet medical need.
1. Out-licensed to Hansoh Pharma (HS 10382) in the Greater China region; Ph1 trial ongoing in China; Terns eligible for up to $67M in clinical, regulatory and sales-based milestones, mid single digit percentage royalties on set sales; Certain milestones are subject to the availability of additional data and future funding.